Alpine Immune Sciences (ALPN) Receives Coverage Optimism Rating of 0.27
News stories about Alpine Immune Sciences (NASDAQ:ALPN) have been trending positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alpine Immune Sciences earned a coverage optimism score of 0.27 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.3894766431721 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Alpine Immune Sciences (NASDAQ ALPN) traded down $0.03 during trading on Friday, reaching $11.01. The company had a trading volume of 10,852 shares, compared to its average volume of 11,728. The stock has a market capitalization of $153.26, a PE ratio of -1.16 and a beta of 0.15. The company has a debt-to-equity ratio of 0.05, a quick ratio of 32.38 and a current ratio of 32.38. Alpine Immune Sciences has a 12 month low of $7.20 and a 12 month high of $14.52.
A number of analysts recently commented on the company. Zacks Investment Research cut Alpine Immune Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. ValuEngine cut Alpine Immune Sciences from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $10.83.
Alpine Immune Sciences Company Profile
Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.